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ABSTRACT
Background: Genetic immunization is expected to induce the expression of antigens in a native form. The
encoded peptide epitopes are presented on endogenous MHC molecules, mimicking antigen presentation
during a viral infection. We have explored the potential of enfuvirtide (T20), a short HIV peptide with antiviral
properties, to enhance immune response to HIV antigens. To generate an expression vector, the T20
sequence was cloned into a conventional plasmid, the novel minicircle construct, and a replicon plasmid. In
addition, 3 conventional plasmids that express the envelope of HIV-1 subtypes A, B and C and contain T20 in
their gp41 sequences were also tested. Results: All combinations induced HIV-specific antibodies and cellular
responses. The addition of T20 as a peptide and as an expression cassette in the 3 DNA vectors enhanced
antibody responses. The highest anti-HIV-1 Env titers were obtained by the replicon T20 construct. This
demonstrates that besides its known antiviral activity, T20 promotes immune responses. We also confirm
that the combination of slightly divergent antigens improves immune responses. Conclusions: The
antiretroviral T20 HIV-1 sequence can be used as an immunogen to elicit binding and neutralizing antibodies
against HIV-1. These, or similarly modified gp41 genes/peptides, can be used as priming or boosting
components for induction of broadly neutralizing anti-HIV antibodies. Future comparative studies will reveal








In this paper, we investigate the dual nature of the T20 peptide,
also known as enfuvirtide. It is the first HIV-1 fusion inhibitor
peptide-based drug that was approved for treatment of AIDS
patients, with the brand name Fuzeon.1,2 T20 consists of a 36
amino acid (aa) peptide mimicking the C-terminal heptad helix
sequence close to the membrane`s proximal external region
(MPER) of the HIV-1 envelope.3 T20 blocks one of the early steps
of the viral life cycle before reverse transcription. It can prevent de
novo infection and cell-to-cell viral transmission. The T20 peptide
inserts itself between 2 viral heptad regions of the transmembrane
antigen gp41 and blocks fusion of the virion to the cell membrane.
The properties of the T20 sequence to mimic the C-terminal
heptad region and bind to the N-terminal heptad region were
considered by us to give T20 an advantage when accumulated
in a single molecule. We have previously demonstrated that
T20 multimerization via DOCK-AND-LOCK-mediated con-
jugation to an IgG-carrier increases anti-retroviral activity
10–100-fold.4 The property of site-specific binding of an anti-
gen is also useful to induce immune responses, since complexes
of antigens usually improve immunogenicity.
The MPER of gp41 in HIV is considered to have low immu-
nogenicity, related to its position close to lipid viral and cellular
membranes.5 The T20 peptide might be recognized as an HIV
antigen. The reason is that T20 contains a conserved peptide
(ELDKWA), the so called 2F5 epitope.6 Antibody 2F5 was iso-
lated from a patient with long-standing HIV infection, and was
shown to have broadly neutralizing capacities and clinical effi-
cacy.7 It has been shown that gp41 antibodies do not essentially
impair T20 antiviral effects in the treatment of HIV-infected
patients,8 but little is known about the immunoprotective prop-
erties of antibodies directed to the T20 peptide.
Several authors have attempted induction of antibodies to
the conserved regions of gp41. This was done by using purified
proteins, peptides, and peptide mimetics representing the
MPER, or viral-like particles (VLP). 9-13 None of those gp41
immunogens succeeded in inducing antibodies with the
breadth and neutralizing properties of human monoclonal anti-
bodies (hmAb) 2F5, 4E10 or 10E8, recovered from long-term
infected individuals.14,15 On the other hand, a lipid-modified
gp41 peptide, gp41int-Cys representing 100 amino acids from
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the MPER region of HIV subtype B, was shown to induce both
highly binding antibodies and neutralization.10
We demonstrate that immunization with plasmid-based
constructs encoding the short T20 peptide results in induction
of antibodies to the peptide. This occurs when the epitope is
present in the full HIV-1 envelope, as well as when displayed as
a short peptide. Using a minicircle (MC) construct and a repli-
con-based vector to express T20, we have demonstrated that
the MC-T20, used as enhancer together with an HIV-DNA
envelope plasmid combination (pCMV-EnvABC), strongly
enhanced end-point specific antibody titers as well as cellular
T20-specific interferon gamma (IFNg) responses. The replicon
construct or the MC-T20 together with a heterogeneous plas-
mid mix of pCMV-EnvABC induced antibodies with neutraliz-
ing activity against several subtypes of HIV-1.
Results
Construction of MC and pCMVEE vectors and the design of
the immunization studies
To obtain native configuration and long-term stable expression
of the T20 peptide, the DNA encoding the peptide sequence
was cloned into the pMC parental plasmid and processed to
obtain MC-T20. The same coding sequence was cloned into the
replicon vector pCMVEE. Schematic representations of
MC-T20, pCMV-T20, pCMVEE-T20 and the peptide sequence
of T20 are shown in Fig. 1. In vitro verification of T20 expres-
sion was shown by western blotting in Fig. S1A for MC-T20
and pCMV-T20, and in Fig. S1B for pCMVEE-T20. The design
of immunization studies performed in mice with various vec-
tors and combinations is provided in Table 1 and Table S1.
T20 peptide immunogenicity
As shown in Fig. 2, immunization of mice with the pCMV-
EnvABC induced binding antibodies to HIV-1 Env B at the
same titers as immunization with the T20 peptide. Addition of
the T20 peptide to the pCMV-EnvABC immunization increased
antibody titers significantly. The additive effect of the T20 pep-
tide was seen whether the intramuscular (im), intradermal (id)
or intranasal (ina) immunization routes were used. The highest
serum anti-gp160 B titers of over 20 000 were noted after intra-
nasal immunization and boosting with the T20 peptides (Fig. 2
and Table S1, Group I). Thus, priming with pCMV-EnvABC
and boosting with T20 peptide gave increased binding antibody
levels to the gp160 protein subtype B, compared with pCMV-
EnvABC alone.
IgG serum titers to HIV-1 Gag antigen were not significantly
changed by T20 peptide boosting (not shown, the Gag antigen
served as a control antigen in the binding assay). This result
was expected, since neither T20 nor the pCMV-EnvABC con-
structs contain Gag sequences.
Attempts to verify viral neutralization (see below) with the
sera from Fig. 2 demonstrated neutralizing titers around 200
for subtype B. Sera from these animals (Table S1, Group I) did
not permit extended studies.
Binding antibodies induced by MC-T20 and pCMVEE-T20
Antibody binding induced by MC-T20 and pCMV-EnvABC
were assayed in a cohort of mice (Table S1, Group II). Binding
antibodies to Env C and T20 of low titers (150–830) appeared
after immunization with MC-T20 alone. These titers were
amplified by the replicon vector pCMVEE-T20 (600–10400)
Figure 1. Schematic overview of T20 constructs. New constructs representingMC-T20, pCMV-T20, pCMVEE-T20 and the T20 peptide amino acid sequence with the 2F5 epi-
tope in bold letters.
2850 S. STENLER ET AL.
and by co-delivery of MC-T20 with pCMV-EnvABC (600–
5000) (Table S1). Avidity indices of the murine sera were high
in pooled sera of the group that received pCMV-EnvABC
together with the MC-T20 (0.90) and lower in groups receiving
MC-T20 or pCMVEE-T20 alone (0.51 and 0.38 respectively,
not shown in figures).
The development over time of antibodies to HIV-1 Env and
T20 is illustrated in Fig. 3. The pCMV-EnvABC, which contains
the T20 subtype B sequence in all 3 constructs induced anti-
body to gp140 subtype C. This reactivity was significantly
enhanced by the addition of MC-T20. When testing the same
sera against the T20 peptide antigen, it is notable that the MC-
T20 construct induces antibodies to the T20 peptide. Antibod-
ies of these magnitudes were not induced by pCMV-EnvABC
without the added MC-T20 construct (Fig. 3 and Table S1
Group III).
Neutralizing antibodies induced by T20 DNA constructs
HIV-1 strains of various subtypes were subjected to neutraliza-
tion by the murine sera. Neutralization of HIV-1 strains was
demonstrated more homogeneously in groups immunized with
pCMV-EnvABC together with MC-T20, than in groups which
received pCMV-EnvABC alone (Fig. 4 and 5).
The T20 was added to pCMV-EnvABC as MC-T20, pCMV-
T20 and T20 peptide (Fig. 4). When such T20 additions were
made, titers were generally higher than when pCMV-EnvABC
was given with control DNA such as noncoding pCMV-DNA
(Fig. 4). HIV-1 of subtypes A, B, C and CRF_AE were neutral-
ized (Fig. 4 A-D). This indicates that the T20 acts as a co-
immunogen to plasmids carrying the full Env sequences.
In Fig. 5, pools of sera with high (Fig. 5 A and B) or low (Fig. 5 C
and D) binding titers in ELISA were used for neutralization of
HIV-1 subtypes B and CRF_AE. Neutralization by these serum
pools demonstrated a pattern with low neutralizing titers after
immunization with MC-T20 alone. Titers were increased by the
replicon vector pCMVEE-T20 and by the addition ofmulti-plasmid
pCMV-EnvABC (Fig. 5 and Table S1, Group III).
Neutralizing antibodies induced by pCMV-EnvABC given alone
(pCMV-EnvABC with noncoding pCMV-DNA, Fig. 5) is therefore
most likely due to antibodies induced against other epitopes of the
HIV-1 envelope than those found at T20 of subtype B.
Human mab 2F5 was used as a comparator in both binding
and neutralization assays. Binding specificities to coated T20 as
well as neutralization of the selected HIV subtypes occurred in
a similar fashion with samples from mice immunized with
pCMVEE-T20 as with the site-specific monoclonal antibody
(Fig. 5 and not shown).
Cell-mediated immune responses
Cellular immune responses could be demonstrated by ELISpot
assays of spleen cells frommice receiving pCMV-EnvABCwith and
withoutMC-T20. High IFNg production with the T20 peptide as a
stimulating agent occurred with pCMV-EnvABC with MC-T20
and pCMVEE-T20 (Fig. S2). Cell mediated responses to the T20
antigen were higher with the pCMVEE-T20 than with theMC-T20.
The MC in combination with pCMV-EnvABC elicited an even
higher cellular response. Cellular reactivities to the gp140 C protein
were, however, low (Fig. S2). It is possible that the MC-T20 con-
struct preferentially directed responses to B-cells. Therefore,the
constructs should not be mixed for induction of broad cellular
responses.
A cytokine analysis of individual blood samples was per-
formed to reveal the type of cellular immune responses. Indi-
viduals receiving MC-T20 alone or combined with pCMV-
EnvABC preferentially had increased IL-2, TNFa, IFNg and
IL-12p70, indicating long-standing T-cell activation. The group
receiving pCMVEE-T20 had a different pattern with increased
blood levels of IL-4, IL-5 and IL-10, indicating mainly B-cell
activation (data not shown).
Table 1. Overview of immunization schedules for T20 constructs.
Vaccine component Time points for injections
2 mg of T20 peptideC 100 mg pCMV-EnvABC
(im, id and ina)
0, 3, 6 weeks
2 mg of T20 peptide (im, id and ina) 0, 3, 6 weeks
100 mg pCMV-EnvABC (im, id and ina) 0, 3, 6 weeks
20 mg MC-T20 (id C EP, 2 sites) 0, 2 weeks
2 mg VEE DREP-T20 (id C EP, 2 sites) 0, 2 weeks
20 mg pCMV-EnvABCC 20 mg MC-T20
(id C EP, 2 sites)
0, 4, 8 weeks
20 mg pCMV-EnvABCC 20 mg pCMV-T20
(id C EP, 2 sites)
0, 4, 8 weeks
20 mg pCMV-EnvABCC 20 mg T20 peptide
(id C EP, 2 sites)
0, 4, 8 weeks
20 mg pCMV-EnvABCC 20 mg pCMV-DNA
(id C EP, 2 sites)
0, 4, 8 weeks
40 mg pCMV-DNA (id C EP, 2 sites) 0, 4, 8 weeks
Footnotes: im: intramuscularly, id: intradermally, ina: intranasally,
EP: electroporation.
Figure 2. Antibody titers to HIV-1 gp160 subtype (B) following pCMV-EnvABC and
T20 peptide immunization. Six mice in each group were immunized with pCMV-
EnvABC (20 mg) with T20 peptide (2 mg). Immunogens were given intramuscularly
(im), intradermally (id) or intranasally (ina). Sera or tissue antibody levels were
assayed by ELISA. Median IgG titers and ranges are shown.
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Discussion
Strategies used in HIV vaccine research include the use of
plasmids, viral vectors and proteins that encode or
represent the envelope glycoprotein. Prime-boosting strate-
gies have shown the advantage of inducing strong and
broad humoral and cellular responses. Priming by DNA fol-
lowed by boosting with viral vectors is the most widely-
researched approach, and poxvirus- and adeno-virus-based
vectors have reached the clinical phase. The moderately suc-
cessful HIV-1 vaccine RV144 study used a combination of
an avian pox vector together with adjuvanted Env proteins.
There are still ongoing analyses of correlates of protection
from the RV144 study, although antibodies reactive with
viral envelope components (V1V2 loops of HIV-1) and
antibodies mediating antibody-dependent cellular cytotoxic-
ity (ADCC) that related to protection were described.27,28 It
will therefore be of further interest to investigate whether
antibody functionality differs when induced by antigens in
various expression systems. It has been established that con-
ventional plasmids followed by vaccinia-vector boosts
induced strong and long-lived ADCC antibodies,29-31
although these properties are difficult to investigate in the
murine system.
Our attempts to improve antibody induction to the HIV
virion and infected cell surface were directed at a conserved
amino acid stretch that also has potent anti-retroviral effects.4,32
The T20 peptide is located at the gp41 transmembrane protein
which is important for HIV-1 fusion. This part of the virion is
available for direct immune attack during just a short period of
the viral life cycle, and antibodies may have to utilize cell/virion
lipid membranes for access to bind and neutralize.33 To enhance
native-like immune responses to the gp41 antigen of HIV, and
particularly the small T20 peptide, we constructed vectors of dif-
ferent types: the very small minicircle MC-T20 and the DNA-
launched replicon pCMVEE-T20. The T20-expressing DNAs
were administered either alone or in combination with a plasmid
DNA vaccine expressing full-length HIV envelope genes. The
full-length HIV envelope plasmids were also used in prime-boost
regimens together with the T20 antiviral peptide.
When used in mice, MC-T20 induced production of anti-
bodies to the T20 peptide. This pepide harbors an epitope
(2F5) to which broadly neutralizing antibodies are directed.
MC-T20, given together with pCMV-EnvABC, the HIV-DNA
plasmid combination, strongly enhanced end point titers
against HIV-1 Env gp160 B, gp140 C, and T20. Sera from mice
immunized with pCMV-EnvABC and the T20 plasmid resulted
in increased antibody titers also against other sites of the gp160
HIV protein. Immunization with the pCMVEE-T20 vector
resulted in high titers of HIV-1-binding and -neutralizing anti-
bodies. For induction of functionally neutralizing antibody it is
likely that the T20, 2F5 and other epitopes of the MPER region
should be presented as DNA, preferably in combination with
the full Env sequences, i.e. also other epitopes of Env.34,35 Natu-
rally, using epitopes expressed as peptides from a plasmid as
adjuvant to constructs expressing the full length HIV proteins
can be supplemented with other more traditional adjuvants.12,30
It appears that expression of the small fragment of gp41
represented by T20 has a favorable configuration to induce
neutralizing antibodies, compared with the same amino
acid region in its native configuration in the full gp160 or
gp140 sequence or as a virus-like particle. The most likely
explanation is that the amino acid stretch represented by
T20 is less exposed due to hydrophobicity or location
within or close to sequences that adhere strongly to one
another.36 The pCMV-EnvABC expresses several subtype
representatives of Env, and the extent of such responses
was enhanced by adding constructs expressing solely a sin-
gle peptide of the gp41, the T20 sequence. These added spe-
cificities may not be enough to make a very broad antibody
response, but might benefit from addition of T20 sequences
from yet other subtypes of HIV-1. A further path we will
take is to express T20-like fragments from other subtypes
of HIV-1, to augment broadness of the polyclonal antibody
population.
The final constructs and doses to choose for such expo-
sure in humans is not yet clear. The T20 peptide has been
used as an anti-retroviral drug for many years, the MC-T20
is a small compound with stable but limited expression,
and the pCMVEE-T20 construct includes the expression of
Figure 3. A-B. Anti-gp140 (C) and anti-T20 antibody titers following immunizations with pCMV-EnvABC with and without MC-T20. Five mice in each group were immu-
nized with pCMV-EnvABC (20 mg) with MC-T20 (20 mg); or pCMV-EnvABC (20 mg) with pCMV-DNA (20 mg). Sera were taken and antibodies against gp140 C and T20 pep-
tide measured by ELISA. (See also Table S1, Group II.)
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the replicase, leading to augmented adaptive immunity.18,37
Due to the different nature of these constructs, the doses of
T20 might not have been equivalent in our studies, and it
is quite possible that increased doses of either compound,
or other immunization intervals, could have led to increased
immune responses.
The MC vector is devoid of the bacterial sequences needed
for propagation in the production bacterial strain, such as ori-
gin of replication and the antibiotic-resistance genes commonly
used as selection markers. This results in a vector that consists
only of the expression cassette.38,39 The MC has been shown to
give a higher and more stable expression of the transgene com-
pared with the corresponding plasmid.40 This is not only due
to the possibility of giving a higher dose of therapeutic DNA
when using an MC as compared with a plasmid; it also relates
to increased robustness and diminished heterochromatin
silencing of the vector.41
The MC has been shown to hold promise as a DNA vac-
cine vector.42,43 In a challenge experiment, the MC vector
conferred better protection and elicited a stronger antigen
specific CD8C T-cell response than plasmid DNA.42 When
used in mice as a vector for HIV DNA vaccine, the
humoral and cellular immune response elicited by the MC
was improved as compared with a conventional plasmid
vector.44 We have also shown previously that an MC con-
taining a small cassette can withstand shearing forces to a
greater extent than a larger construct.18 Recently, a promis-
ing technique was published showing that production in a
ligase-mediated and bending protein-assisted circularization
reaction at high DNA concentration may greatly amplify
MC production.45
The second vector used in this study is the novel non-
integrative avirus replicon. The avirus genus is a group of
enveloped viruses that belongs to the Togaviridae family.
Figure 4. A-D. Neutralization titers to HIV-1 of subtypes A, B, (C) and CRF_AE. Five mice in each group were immunized with pCMV-EnvABC (20 mg) and MC-T20 20 mg;
pCMV-EnvABC (20 mg) and pCMV-T20 (20 mg); pCMV-EnvABC (20 mg) and T20 peptide (10 mg); pCMV-EnvABC (20 mg) and non-coding pCMV-DNA (20 mg); or non-coding
pCMV-DNA (40 mg). The p24 ELISA was used to detect subtype A, B and C viral antigen inhibition, the RT assay to detect CRF_AE viral antigen inhibition. (See also
Table S1, Group III.)
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When the virus’ structural genes are replaced by foreign
genes of interest, they generate self-replicating RNA (repli-
cons) that express foreign gene(s) in transfected cells. Repli-
cons have been shown to produce high amounts of
heterologous proteins in transfected cells. The mRNA
downstream of the 26S promoter is produced in 10-fold
molar excess when compared with genomic RNA.21 In the
present paper, pCMVEE-T20 constructs launched from plas-
mid DNA with a CMV promoter had the highest T20 pep-
tide expression and induced the highest antibody titers
binding to the T20 peptide.
A few publications have described expression of HIV-1
gp41 fragments. Dervillez et al. have previously expressed
the C46 T20-like peptide in vitro as a multimeric fusion
protein, which was shown to have an antiviral effect
in vitro.46 They also expressed the peptide as a monomer
and could show expression but no secretion of the peptide.
However, they did not study the immunogenicity of their
peptide construct. For immunostimulation, secretion is not
crucial, since the transfected cells present the endogenously-
produced antigen on MHC molecules. Expression of pepti-
des as short as 36 amino acids is not trivial; in nature they
are often produced as part of a pre-protein or as multimers
which are then cleaved. Here, we show that the T20 peptide
can be expressed from different DNA-based vectors and
induce HIV-specific immune responses.
In humans, adaptive antibody responses to HIV-1 envelope
antigens of gp41 and gp120 occur weeks after primary HIV-
infection. The quality of these antibodies is important for deter-
mining viral set-point levels, since a continuous escape of both
antibody and cellular immune reactivity makes antibodies to
variable sites of the virus only partially effective in reducing
Figure 5. A-D. Neutralization titers to HIV-1 of subtypes (B) and CRF_AE. Five mice in each group were immunized with pCMV-EnvABC (20 mg) with MC-T20 (20 mg); or
MC-T20 (20 mg); or pCMVEE-T20 (2 mg). Sera were taken, divided into pools of sera with higher ELISA titers (A and B) and lower binding titers (C and D), and neutralization
performed. The p24 ELISA was used to detect subtype B viral antigen inhibition, the RT assay to detect CRF_AE viral antigen inhibition. Positive sera consisted of hmAb
2F5 (inverted triangles) and 4E10 (diamonds). (See also Table S1, Group II.)
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viral loads. Antibodies that broadly neutralize several tiers and
subtypes of HIV-1 are usually directed toward less variable
sites, and occur late in disease.15,47
Although the effective time for antibodies to bind and neu-
tralize via the MPER- regions is short, it was demonstrated that
broadly neutralizing antibodies properties decreased viral load
for a considerable time in HIV-infected patients.7 The studies
of passive immunization appear to have an increased effect
when a combination of antibodies is used. This may be due to
an altered configuration of the envelope gp120 trimer,4
improved by the combination of antibodies with different tar-
gets on the Env protein.48,49
The MPER region of gp41 is considered to be of low immu-
nogenicity, which is possibly related to its position close to viral
and cellular lipid membranes.5,50,12,49 Our induced immune
reactivity to the T20 peptide of MPER was considered to result
from the fact that the peptide mimics residues of the HIV-1 gly-
coprotein gp41. The CD4Cmolecule acts as the primary recep-
tor of HIV-1. The antigen gp41 binds to the target cell through
integration of the gp41 fusion peptide, before the formation of
a 6-helix bundle. This permits viral attachment to the CCR5
cell surface co-receptor. Thus, antibodies or cellular reactivity
formed against the T20 peptide or its epitopes will also find
epitopes at the HIV-1 transmembrane protein of the virion
during infection. The same properties that make T20 a very
efficient antiviral during long-term exposure4 may thus be the
reason that gene-expressed T20 induces neutralizing antibodies
when administered as DNA.
In these studies we used neutralization assays with
viruses of different subtypes, which replicate well in vitro.
Other types of assays such as pseudovirion inhibition or
antibody-dependent assays would have made our results
more comparable with those of human or non-primate
immunization studies. The sample sizes from mice did not
permit further analyses. We have however shown previously
that results from our murine studies mirror the broadness
and subtype reactivities seen in immunized humans from
several countries and with various genetic back-
grounds.17,26,34,35 The possibility to assay T20 or sequences
homologous to gp41 of SIV as immunogens might be fur-
ther explored in non-human primates. In this situation, the
gp41 fragments may act independently to boost antiviral
responses to the homologous transmembrane regions.
The murine Fab has a different configuration from human
IgG, but it was still possible to induce and identify stem cells
with genes for the desired broadly neutralizing activities from
HIV-immunized mice which had been knocked-in for human Ig
production.51 The T20 antigen is not very immunogenic when
given as a peptide to infected humans,8 and induction of neutral-
izing antibody has not been shown. The individuals who receive
the T20 treatment are highly immunosuppressed. Therefore, it is
likely that T20 or similar molecules expressed intracellularly by
DNA constructs in immunocompetent humans might induce or
boost functional antibodies with variable Fab chains similar to
the stem cell variants described by Sok et al.51
The expression of small, defined sequences of hidden epito-
pes from HIV can thus possibly lead to development of new




Peptide (Fig. 1): The T20 peptide derived from HXB2 of HIV-1
subtype B is a linear 36 amino acid peptide used as a fusion
inhibitor in anti-retroviral therapy (Roche Molecular Systems,
USA). The peptide amino acid sequence is as follows: YTSLIH-
SLIEESQNQQEKNEQELLELDKWASLWNWF; with the 2F5
epitope in bold.
pCMV-EnvABC: This compound consists of 3 plasmids con-
taining gp160 genes from HIV-1 subtypes A, B, and C.16 They
were produced by homologous recombination where 75% of
the original subtype B of pCMV-gp160 (pCMV-EnvB) was
substituted for sequences found in subtypes A and C.16,17 The
constructs also contain a CMV promoter, an HPV16 polyA sig-
nal, and a kanamycin resistance gene (KmR). One of these plas-
mids, pCMV-EnvB, was used as a donor vector for the
expression cassette to produce pCMV-T20 and MC-T20 (see
below). pCMV-DNA, which does not contain any expression
cassette, was used for control immunizations.
Minicircle MC-T20 (Fig. 1): The nucleotide (nt) sequence for
the T20 peptide with a secretion signal (ss) from the V-J2-C
region of the mouse Ig kappa-chain for efficient secretion of
recombinant proteins (Immunomedics Inc., Morris Plains, NJ,
USA)4 was cloned into the pCMV-T20 plasmid (see pCMV-
EnvABC) using Fse I and EcoRV restriction sites, by enzymes
from New England Biolabs (R0588S and R0195S, NEB). PCR
was performed to amplify the ss-T20 gene fragment (Eurofins
Genomics, DE). The whole expression cassette was cloned into
a pMC-vector, using its restriction sites18 to produce MC-T20.
The resulting construct was transformed into the
ZYCY10P3S2T bacterial strain and expanded overnight. MC-
T20 induction and purification were performed according to
Kay et al.19 The cloned sequences were confirmed by sequenc-
ing (Eurofins Genomics). The resulting MC-T20 was 1.1 kb
which is less than one third of a corresponding conventional
plasmid.
To assess expression, pCMV-T20 and MC-T20 were
transfected into HeLa, HEK293 and U2OS cells by polye-
thyleneimine (PEI) or lipofectamine (BMS1003 and
11668027, ThermoFisher Scientific). Crude cell lysate was
run on a 20% TBE gel. After transfer to a nitrocellulose
membrane by an iBlotter (Invitrogen Life Technologies,
SE), the membrane was incubated with anti-HIV Env
human monoclonal antibodies hmAb 2F5 or 4E10 (gener-
ous gifts from H. and D. Katinger, Polymun Scientific), and
then with goat-anti-human IgG labeled with IRDye 680LT
(925–68078 LI-COR).
pCMVEE-T20 (Fig. 1): We cloned the HIV T20 sequence
used in the pCMV-T20 and MC-T20 constructs above into the
multiple cloning site (MCS) of the pCMVEE vector to generate
the pCMVEE-T20 plasmid using the EcoRV and Fse I restric-
tion sites. pCMVEE is a DNA-launched avirus replicon vector
based on the Venezuelan Equine Encephalitis virus (VEE).20
The replicon is under the control of the CMV promoter and
encodes the viral replicase, the internal 26S promoter followed
by the T20 gene and the viral polyA. After transcription of the
replicon mRNA, the 50 end of the parental genome encoding
the viral replicase is translated in the cytoplasm. Next, the
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replicase catalyzes the transcription of a negative sense copy of
the genome, which serves as a template for new replicon RNA,
as well as for high level transcription of sub-genomic mRNA
from the internal 26S promoter.21 pCMVEE-T20 cloning was
confirmed by sequencing (Eurofins Genomics).
Eukaryotic expression of T20 from pCMVEE-T20 was
confirmed in baby hamster kidney (BHK) cells. Transfection
was performed using lipofectamine 2000 (11668027, Ther-
moFisher Scientific) according to the manufacturer’s
instructions. After 24 h, cells and supernatants were har-
vested, denatured and run on an SDS-PAGE, and blotted to
a PVDF membrane before T20 was detected using hmAb
2F5 (AB001, Polymun Scientific), followed by HRP-conju-
gated rabbit anti-human IgG (Sigma-Aldrich, MO, USA).
The membranes were developed with enhanced chemilumi-
nescent substrate (Pierce ECL Western Blotting Substrate,
32106 Thermo Fisher Scientific), and visualised with a
ChemiDoc MP imaging system (Bio-Rad, CA, USA).
Murine immunization
Female BALB/c mice 8–12 weeks of age were purchased from
Scanbur Research (Sollentuna, Sweden) and kept at the Depart-
ment of Microbiology, Tumor and Cell Biology, Karolinska
Institutet. A summary of the immunization studies is provided
in Table 1 and Supplementary, with additional parameters
described in the figure legends. All mice were of the same
strain, from the same deliverer, of the same gender and similar
ages. They were were immunized with T20 peptide, MC-T20,
pCMV-T20, pCMV-EnvABC, pCMVEE-T20 and/or control
pCMV-DNA to assess the serological and cellular responses.
The mice were given protein/peptides intramuscularly (im),
intradermally (id) or intranasally (ina), and gene constructs
intradermally by needle (id) followed by electroporation (EP).
EP was performed by DermaVax skin delivery system (Cellec-
tis, Paris, FR), which has a needle array electrode with two
parallel rows of four 2-mm pins.22,23
Immunological assays
Enzyme-linked immunosorbent assay
ELISA was performed with baculovirus recombinant protein
subtype B gp160/LAV (2000 LAV, Protein Sciences), recombi-
nant HIV-1 antigen CN54 gp140 C (ENV002, Polymun) the
gp41 peptides T20 and P18 from subtype B and HIV-1 Gag
p24 antigen (Los Alamos database, http://www.hiv.lanl.gov/
and Thermohybaid, DE). Microplates (243656, Nalge-Nunc)
were coated with proteins (1 mg/well) or peptide (10 mg/well)
in 200 ml/well and sera were assayed as described.24 Avidity
indices were determined after urea elution of antibodies using
7 M urea. ELISA titers were determined by interpolating the
dilution at which the dilution curve reaches the defined cutoff
value using GraphPad Prism software (CA, USA).
Neutralization assay
Viral isolates were derived from subtype A 92UG29/WHO
strain, subtype B strain IIIB LAI X4, subtype B SF162 R5,
B/6920 R5, HIV-1 B/6794 £ 4, HIV-1 C J10687 R5 and
HIV-1 CRF01_AE 1545 (http://www.hiv.lanl.gov). The panel
was selected to include both X4 and R5 strains and to be related
to the pCMV-EnvABC plasmid immunogen.25 Sera were
diluted in RPMI 1640 supplemented with 5% FCS and antibiot-
ics (61870–010, ThermoFisher Scientific) in 96-well tissue cul-
ture plates (260860, ThermoFisher Scientific). Each dilution
was mixed with virus of a simultaneously determined TCID50
and incubated at 37C for 1 h followed by the addition of 105
human PBMCs activated by phytohemagglutinin (PHA) and
rIL-2 (200–02, PeproTech) or C8166.CCR5 receptor-rich cells.
The cells were incubated over night at 37C in 5% CO2 in air,
and washed twice with RPMI 1640 before they received new
medium. After 5–7 d of culture, the presence of HIV-1 p24
antigen in the culture medium was measured by ELISA for
HIV-1 subtypes A and B or the Lenti-RT assay (51010,
CavidiTech) for HIV-1 subtypes C and CRF01_AE. The back-
ground of the p24 ELISA was determined for each plate and
subtracted from all wells. The percentage of neutralization was
determined as [1-(mean p24 OD in the presence of test serum/
mean p24 OD in the absence of test serum)] £ 100. CavidiTech
results were calculated as pg of RT/ml.
ELISpot assays
Interferon gamma (IFNg) Enzyme Linked ImmunoSpot
(ELISpot) was used to determine the frequency of IFNg
producing T cells after stimulation with proteins or pepti-
des. Plates (MAIPSWU10, Millipore) were coated with IFN-
g capture antibodies according to the manufacturer’s
instructions (3420–3–250, MabTech). Splenocytes were pre-
pared as described.24,26 A total of 2 £ 105 cells were plated
per well and stimulated for 21 C/- 2 h with peptides/pro-
teins of HIV-1. Concanavalin A (C5275–5MG, Sigma-
Aldrich) was used as a positive control, and culture medium
(MDEM with 2 mM L-glutamine, 1% Penicillin-Streptomy-
cin and 5% bovine calf serum) as negative control. ELISpots
were developed with biotinylated detection Mab R4–6A2
(1 mg/ml) followed by streptavidine alkaline phosphatase
(ALP) and 5-bromo-4-chloro-3-indolyl phosphate-nitroblue
tetrazolium (BCIP/NBT) substrate. The number of spot-
forming cells (SFCs) was determined using an ELISpot
reader (BioReader Autoplate 5000, BioSys, Karben, DR).
Cytokines secreted by spleen cells were measured by Bio-
Plex Pro Mouse Cytokine assay TH1/TH2 panel 8-Plex
according to the manufacturer’s protocol (BioRad, Rich-
mond, CA, USA). In brief, 25 ml of serum mixed with assay
diluent was added to cytokine beads labeled with anti-TH1
and anti-TH2 cytokine antibodies. Standard curves for each
cytokine were used to determine cytokine concentration/ml
of serum. Control serum was derived from a pool of non-
immunized mice.
Statistical analysis
Statistical analyses were performed using Prism 5 GraphPad
Software, (CA, USA). Statistical methods used were the non-
parametric Mann-Whitney U test and Kruskal-Wallis
non-parametric analysis with Dunns correction.
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